Vancomycin Hydrochloride for Injection Product Launches – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Officials with Xellia Pharmaceuticals (‘Xellia’) announced they have launched Vancomycin Hydrochloride for Injection, USP within the United States market.
The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.
“Today marks an important milestone for our US market strategy and represents a significant step forward in the company’s evolution as we bring the first product to the US market under the Xellia brand,” Carl-Aake Carlsson, Xellia’s CEO, said in a prepared statement about the launch.